Drugs / CTAP201
last change Oct 2009 re-read 2 minutes ago

CTAP201

Developed for
chronic renal failure syndrome · secondary hyperparathyroidism of renal origin
Investigated by
OPKO IP Holdings II, Inc.

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00792857 Nov 2008 → Sep 2009 chronic renal failure syndrome, secondary hyperparathyroidism of renal origin OPKO IP Holdings II, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CTAP201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00792857
Route Intravenous “I.V. CTAP201” NCT00792857